UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)

Nederlands Tijdschrift voor Diabetolog, 2013-09, Vol.11 (3), p.79-80

2013

Volltextzugriff (PDF)

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

The 12-Item Hypoglycemia Impact Profile (HIP12): psychometric validation of a brief measure of the impact of hypoglycemia on quality of life among adults with type 1 or type 2 diabetes

BMJ open diabetes research & care, 2022-08, Vol.10 (4), p.e002890

2022

Volltextzugriff (PDF)

127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

1611-P: Assessment of Fatty Acid Uptake by PET/MRI Imaging Under Fasting and Postprandial Conditions—A Repeatability Study in People with T2DM and Obesity

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

357-OR: Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

943-P: Role of Model-Informed Drug Development in Confirming Additional Clinical Benefits of Dulaglutide

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

980-P: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Assessing the Content Validity, Acceptability, and Feasibility of the Hypo-METRICS App: Survey and Interview Study

JMIR diabetes, 2023-09, Vol.8, p.e42100-e42100

2023

Volltextzugriff (PDF)

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Diabetes care, 2017-05, Vol.40 (5), p.647-654

2017

Volltextzugriff (PDF)

Association of hyperglycemia and insulin with diabetic cardiovascular complications

The Israel Medical Association journal, 2003-02, Vol.5 (2), p.116-119

2003

Volltextzugriff (PDF)

Association of PAX3 and TMTC2 gene polymorphism with the face morphology change after excision of skin tumors

Vojnosanitetski pregled, 2020, Vol.77 (6), p.631-636

2020

Volltextzugriff (PDF)

Better Glycemic Control and Less Weight Gain with Once Weekly Dulaglutide vs. Once Daily Insulin Glargine, Both Combined with Pre-Meal Insulin Lispro, in Type 2 Diabetes Patients (AWARD-4)

Canadian journal of diabetes, 2014-10, Vol.38 (5), p.S50-S50

2014

Volltextzugriff (PDF)

Beyond glycemia

Diabetes care, 1995-07, Vol.18 (7), p.1037-1041

1995

Volltextzugriff (PDF)

Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities

The Israel Medical Association journal, 2003-11, Vol.5 (11), p.801-806

2003

Volltextzugriff (PDF)

Comparative efficacy of preprandial or postprandial humalog ® mix75/25™ versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus

Clinical therapeutics, 2002, Vol.24 (1), p.73-86

2002

Volltextzugriff (PDF)

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy

Diabetes, obesity & metabolism, 2016-10, Vol.18 (10), p.999-1005

2016

Volltextzugriff (PDF)

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2021-02, Vol.106 (2), p.388-396

2021

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(89)
Webseiten
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(48)
Science & Technology
(48)
Humans
(40)
Diabetes
(37)
Endocrinology & Metabolism
(35)
Diabetes Mellitus, Type 2 - Drug Therapy
(26)
Female
(25)
Male
(25)
Middle Aged
(24)
Diabetes Mellitus
(21)
Insulin
(20)
Aged
(18)
Hypoglycemic Agents - Therapeutic Use
(17)
Antidiabetics
(16)
Glucagon
(15)
Diabetes Mellitus, Type 2 - Blood
(14)
Hypoglycemic Agents - Administration & Dosage
(14)
Type 2 Diabetes
(14)
Clinical Trials
(13)
Treatment Outcome
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

The 12-Item Hypoglycemia Impact Profile (HIP12): psychometric validation of a brief measure of the impact of hypoglycemia on quality of life among adults with type 1 or type 2 diabetes

127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity

128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

1611-P: Assessment of Fatty Acid Uptake by PET/MRI Imaging Under Fasting and Postprandial Conditions—A Repeatability Study in People with T2DM and Obesity

338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

357-OR: Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11

714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function

943-P: Role of Model-Informed Drug Development in Confirming Additional Clinical Benefits of Dulaglutide

980-P: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients

993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes

Assessing the Content Validity, Acceptability, and Feasibility of the Hypo-METRICS App: Survey and Interview Study

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Association of hyperglycemia and insulin with diabetic cardiovascular complications

Association of PAX3 and TMTC2 gene polymorphism with the face morphology change after excision of skin tumors

Better Glycemic Control and Less Weight Gain with Once Weekly Dulaglutide vs. Once Daily Insulin Glargine, Both Combined with Pre-Meal Insulin Lispro, in Type 2 Diabetes Patients (AWARD-4)

Beyond glycemia

Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities

Comparative efficacy of preprandial or postprandial humalog ® mix75/25™ versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Suchergebnisse filtern